AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17394986 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate procedural sedation (PS) target
Number of subjects: 75
Study 17394986 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep procedural sedation (PS) target
Number of subjects: 75
Study 15542184 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 729
Study 15542184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 729
Study 15542184 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 729
Study 11412051 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 22
Study 11412051 — intervention group
Group type: COMPARATOR
Intervention: NCEP-1 diet
Number of subjects: 22
Study 9783557 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning light (10,000 lux, 30 min/d)
Number of subjects: 158
Study 9783557 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening light (10,000 lux, 30 min/d)
Number of subjects: 158
Study 9783557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density negative air ionization (2.7 x 10(6) ions/cm³, 30 min/d in the morning)
Number of subjects: 158
Study 9783557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density negative air ionization (1.0 x 10(4) ions/cm³, 30 min/d in the morning)
Number of subjects: 158
Study 8006284 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (75 mg daily)
Number of subjects: 15
Study 8006284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29290017 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight bearing exercise (WBE)
Number of subjects: 19
Study 29290017 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise (RE)
Number of subjects: 19
Study 27894540 — intervention group
Group type: EXPERIMENTAL
Intervention: AcceleDent (20 minutes a day)
Number of subjects: 81
Study 27894540 — intervention group
Group type: COMPARATOR
Intervention: AcceleDent sham device
Number of subjects: 81
Study 27894540 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliances only
Number of subjects: 81
Study 25613949 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric intraocular pressure (IOP) sensor implantation
Number of subjects: 6
Study 25613949 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric IOP measurement
Number of subjects: 6
Study 25613949 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-tonometry at home
Number of subjects: 6
Study 23758456 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible-light curing of pulp capping compounds (Groups 1-7)
Number of subjects: 100
Study 23758456 — intervention group
Group type: COMPARATOR
Intervention: Diode laser irradiation without prior application of a pulp capping compound (Groups 8-10)
Number of subjects: 100
Study 21963329 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA
Number of subjects: 153
Study 21963329 — intervention group
Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 153
Study 21963329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 153
Study 19285304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion for the first 24 hours after surgery
Number of subjects: 22
Study 19285304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 22
Study 19285304 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 22
Study 17079189 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting nifedipine
Number of subjects: 7665
Study 17079189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7665
Study 15096083 — intervention group
Group type: EXPERIMENTAL
Intervention: 7000 lux (active) light box
Number of subjects: 10
Study 15096083 — intervention group
Group type: COMPARATOR
Intervention: 500 lux (placebo) light box
Number of subjects: 10
Study 11518073 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (Ze 117; 500 mg extract/day)
Number of subjects: 240
Study 11518073 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 240
Study 9457399 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous rIL-2 alone
Number of subjects: 0
Study 9457399 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous rIL-2 plus rIFN-alpha
Number of subjects: 0
Study 9457399 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose outpatient subcutaneous rIL-2 plus rIFN-alpha
Number of subjects: 0
Study 9457399 — intervention group
Group type: COMPARATOR
Intervention: Outpatient rIL-2/rIFN-alpha plus 5-FU/rIFN-alpha
Number of subjects: 0
Study 7930542 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ampicillin/sulbactam
Number of subjects: 128
Study 7930542 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin and metronidazole
Number of subjects: 128
Study 2905387 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage chlorthalidone
Number of subjects: 4736
Study 2905387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study 29973251 — intervention group
Group type: EXPERIMENTAL
Intervention: Authentic N95 facemasks
Number of subjects: 15
Study 29973251 — intervention group
Group type: COMPARATOR
Intervention: Sham N95 facemasks
Number of subjects: 15
Study 27479536 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-step treatment for MDD after failing initial antidepressant trial
Number of subjects: 1522
Study 27479536 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-step treatment for MDD
Number of subjects: 1522
Study 25799445 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion (RPE) and facial mask (FM) therapy
Number of subjects: 21
Study 25799445 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - untreated Class III patients
Number of subjects: 21
Study 23865512 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA)
Number of subjects: 90
Study 23865512 — intervention group
Group type: COMPARATOR
Intervention: Control (sham acupressure)
Number of subjects: 90
Study 21083927 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing (warfarin therapy based on algorithms using clinical information and genotypes for polymorphisms in CYP2C9 and VKORC1)
Number of subjects: 1238
Study 21083927 — intervention group
Group type: COMPARATOR
Intervention: Clinical-guided dosing (warfarin therapy based on algorithms using only clinical information)
Number of subjects: 1238
Study 18757777 — intervention group
Group type: EXPERIMENTAL
Intervention: PET(−) patients
Number of subjects: 817
Study 18757777 — intervention group
Group type: COMPARATOR
Intervention: PET(+) patients
Number of subjects: 817
Study 18757777 — intervention group
Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 817
Study 16369994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen or toremifene alone or in combination with chemotherapy (either concurrently or sequentially)
Number of subjects: 4948
Study 16369994 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy alone (tamoxifen or toremifene)
Number of subjects: 4948
Study 16369994 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy or beyond 3 months after completing chemotherapy
Number of subjects: 4948
Study 16369994 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 4948
Study 16369994 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy
Number of subjects: 4948
Study 14659376 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trial (RConT)
Number of subjects: 0
Study 14659376 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised comparison trial (RComT)
Number of subjects: 0
Study 14659376 — intervention group
Group type: EXPERIMENTAL
Intervention: Other experimental designs
Number of subjects: 0
Study 10817373 — intervention group
Group type: EXPERIMENTAL
Intervention: True provocation to electric and magnetic fields
Number of subjects: 15
Study 10817373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham provocation to electric and magnetic fields
Number of subjects: 15
Study 10817373 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 15
Study 8941016 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt testicular leukemia
Number of subjects: 651
Study 8941016 — intervention group
Group type: COMPARATOR
Intervention: No overt testicular leukemia
Number of subjects: 651
Study 1512327 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy (5,000 U bolus followed by 1,000 U/h continuous infusion)
Number of subjects: 281
Study 1512327 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 281
Study 1512327 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy (optimal anticoagulation)
Number of subjects: 281
Study 1512327 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy (suboptimal anticoagulation)
Number of subjects: 281
Study 1512327 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy (inadequate anticoagulation)
Number of subjects: 281
Study 1512327 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy
Number of subjects: 281
Study 6527973 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5mg intravenous nicardipine
Number of subjects: 20
Study 6527973 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg intravenous nicardipine
Number of subjects: 20
Study 31805981 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and aerobic and functional exercises
Number of subjects: 0
Study 31805981 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional program including only resistance and aerobic exercises
Number of subjects: 0
Study 31805981 — intervention group
Group type: COMPARATOR
Intervention: Usual care program
Number of subjects: 0
Study 30442501 — intervention group
Group type: COMPARATOR
Intervention: dinutuximab beta alone
Number of subjects: 406
Study 30442501 — intervention group
Group type: EXPERIMENTAL
Intervention: dinutuximab beta with subcutaneous IL-2
Number of subjects: 406
Study 26846357 — intervention group
Group type: EXPERIMENTAL
Intervention: Active supplementation (encapsulated fruit and vegetable powder)
Number of subjects: 0
Study 26846357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25180702 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (15-20 minutes, up to 6 times weekly for 12 months)
Number of subjects: 340
Study 25180702 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 340
Study 25180702 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 340
Study 22160145 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy
Number of subjects: 225
Study 22160145 — intervention group
Group type: COMPARATOR
Intervention: Darunavir/ritonavir triple therapy
Number of subjects: 225
Study 20813583 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (maximum 3mg/24h)
Number of subjects: 67
Study 20813583 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 67
Study 17430326 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 90
Study 17430326 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron-dexamethasone combination (granisetron 40 microg/kg and dexamethasone 150 microg/kg)
Number of subjects: 90
Study 17430326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 90
Study 15478386 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cough treatment
Number of subjects: 28
Study 15478386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15478386 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sessions (days 1 and 2)
Number of subjects: 28
Study 11892004 — intervention group
Group type: EXPERIMENTAL
Intervention: KneeNavTM ACL (computer-assisted surgical navigation technique)
Number of subjects: 20
Study 11892004 — intervention group
Group type: COMPARATOR
Intervention: Traditional arthroscopic technique
Number of subjects: 20
Study 9506736 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection therapy
Number of subjects: 50
Study 9506736 — intervention group
Group type: COMPARATOR
Intervention: Suppressive doses of L‐T4
Number of subjects: 50
Study 7871648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton
Number of subjects: 133
Study 7871648 — intervention group
Group type: COMPARATOR
Intervention: HBsAg carriers
Number of subjects: 133
Study 7871648 — intervention group
Group type: COMPARATOR
Intervention: Patients with chronic diffuse liver diseases
Number of subjects: 133
Study 7871648 — intervention group
Group type: COMPARATOR
Intervention: Patients with uveitis
Number of subjects: 133
Study 3411388 — intervention group
Group type: COMPARATOR
Intervention: Food hypersensitivity evaluation through double-blind placebo-controlled food challenges
Number of subjects: 46
Study 3411388 — intervention group
Group type: COMPARATOR
Intervention: Food challenges
Number of subjects: 46
Study 3411388 — intervention group
Group type: COMPARATOR
Intervention: Food hypersensitivity reactions (egg, milk, peanut)
Number of subjects: 46
Study 3411388 — intervention group
Group type: COMPARATOR
Intervention: Symptoms during food challenges
Number of subjects: 46
Study 30704923 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 200 mg (100 mg for east Asians) once daily during induction chemotherapy
Number of subjects: 148
Study 30704923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 30704923 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 148
Study 28641384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron® injections (7.5 mg)
Number of subjects: 32
Study 28641384 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study 28641384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron and testosterone (L+T) replacement for 49 days
Number of subjects: 32
Study 27131419 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 40μg.kg(‐1)
Number of subjects: 60
Study 27131419 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 20μg.kg(‐1)
Number of subjects: 60
Study 27131419 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 10μg.kg(‐1)
Number of subjects: 60
Study 27131419 — intervention group
Group type: COMPARATOR
Intervention: Placebo with atropine
Number of subjects: 60
Study 24403557 — intervention group
Group type: EXPERIMENTAL
Intervention: JS7 DNA vaccine and MVA/HIV62B (DDMM regimen)
Number of subjects: 299
Study 24403557 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B (MMM regimen)
Number of subjects: 299
Study 24403557 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 299
Study 22275160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil 40 mg
Number of subjects: 17
Study 22275160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil 80 mg
Number of subjects: 17
Study 22275160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22275160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (40 mg or 80 mg)
Number of subjects: 17
Study 19382501 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied mytomycin-C (MMC) for 5 minutes
Number of subjects: 38
Study 19382501 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control) for 5 minutes
Number of subjects: 38
Study 17893256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-leg (exercising leg)
Number of subjects: 7
Study 17893256 — intervention group
Group type: COMPARATOR
Intervention: Rest-leg (resting leg)
Number of subjects: 7
Study 17893256 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating IGFBP-1
Number of subjects: 7
Study 17893256 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 7
Study 14705120 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic deep brain stimulation
Number of subjects: 16
Study 11459446 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood‐based repeated measures analyses (MMRM)
Number of subjects: 0
Study 11459446 — intervention group
Group type: COMPARATOR
Intervention: Last observation carried forward approach (LOCF)
Number of subjects: 0
Study 10448446 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer befriending intervention
Number of subjects: 0
Study 10448446 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0
Study 7602350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 5 g/m2 by 24-hour continuous intravenous infusion with mesna on day 1, carboplatin 300 mg/m2 intravenously on day 1, etoposide 50 mg/m2 orally on days 1 to 21 every 4 weeks (schedule I)
Number of subjects: 35
Study 7602350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 3.75 g/m2 IV on day 1, carboplatin 300 mg/m2 IV on day 1, etoposide 50 mg orally on days 1 to 14 (schedule II)
Number of subjects: 35
Study 7602350 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (ICE regimen)
Number of subjects: 35
Study 2085990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 grams, single dose)
Number of subjects: 60
Study 2085990 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (400 mg b.i.d. for 7 days)
Number of subjects: 60
Study 282070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg, orally)
Number of subjects: 27
Study 282070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (sublingual route)
Number of subjects: 27
Study 282070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (in five patients with hypertensive crisis)
Number of subjects: 27
Study 31207253 — intervention group
Group type: EXPERIMENTAL
Intervention: High soy protein (HSP; 50 g)
Number of subjects: 17
Study 31207253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low soy protein (LSP; 25 g)
Number of subjects: 17
Study 31207253 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; 50 g carbohydrate)
Number of subjects: 17
Study 31207253 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin response
Number of subjects: 17
Study 31207253 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin response
Number of subjects: 17
Study 28182508 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOI
Number of subjects: 14
Study 28182508 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOR
Number of subjects: 14
Study 28182508 — intervention group
Group type: COMPARATOR
Intervention: PLAI
Number of subjects: 14
Study 28182508 — intervention group
Group type: COMPARATOR
Intervention: PLAR
Number of subjects: 14
Study 25991760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprecipitate (CRYO)
Number of subjects: 43
Study 25991760 — intervention group
Group type: COMPARATOR
Intervention: Standard major haemorrhage therapy (STANDARD)
Number of subjects: 43
Study 23795754 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-IAP
Number of subjects: 229
Study 23795754 — intervention group
Group type: COMPARATOR
Intervention: IAP
Number of subjects: 229
Study 23795754 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 PCR assay
Number of subjects: 229
Study 22664119 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 75 mg/kg/day TDS orally with deferoxamine 30-50 mg/kg subcutaneously every other day
Number of subjects: 26
Study 22664119 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine 30-50 mg/kg/day subcutaneously for 6-12 hours/day and 5-6 days per week
Number of subjects: 26
Study 19097925 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA-based system
Number of subjects: 93
Study 19097925 — intervention group
Group type: COMPARATOR
Intervention: Paper-based system
Number of subjects: 93
Study 17524772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneled scleral incision
Number of subjects: 88
Study 17524772 — intervention group
Group type: COMPARATOR
Intervention: Straight scleral injection
Number of subjects: 88
Study 15374722 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial laser intrauterine thermal therapy (ELITT)
Number of subjects: 116
Study 15374722 — intervention group
Group type: COMPARATOR
Intervention: Transcervical hysteroscopic endometrial resection (TCRE)
Number of subjects: 116
Study 15374722 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ELITT and TCRE
Number of subjects: 116
Study 11583481 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once daily
Number of subjects: 25
Study 11583481 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 25
Study 11583481 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once daily
Number of subjects: 25
Study 11583481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9539615 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl starch (ACS) 6% i.v. at 15 mL/kg up to 1000 mL
Number of subjects: 32
Study 9539615 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) 6% i.v. at 15 mL/kg up to 1000 mL
Number of subjects: 32
Study 9539615 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl starch (ACS)
Number of subjects: 32
Study 9539615 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 32
Study 7855219 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg naloxone
Number of subjects: 0
Study 7855219 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg naloxone
Number of subjects: 0
Study 7855219 — intervention group
Group type: COMPARATOR
Intervention: Control infusions
Number of subjects: 0
Study 2680086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 30
Study 2680086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 351232 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 16
Study 351232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30671872 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hourly repositioning 24/7
Number of subjects: 80
Study 30671872 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating pressure air mattress (recommended intervention)
Number of subjects: 80